Pharma & Healthcare
Global Oncology Immuno Drug Market Insights, Forecast to 2030
- Mar 11, 25
- ID: 4377
- Pages: 95
- Figures: 117
- Views: 53
Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.
The global Oncology Immuno Drug market is projected to grow from US$ 2365 million in 2024 to US$ 3807.5 million by 2030, at a Compound Annual Growth Rate (CAGR) of 8.3% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Oncology Immuno Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Oncology Immuno Drug, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Oncology Immuno Drug, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Oncology Immuno Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Oncology Immuno Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Oncology Immuno Drug sales, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Roche AG
AstraZeneca
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
Merck KGaA
Segment by Type
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Other
Segment by Application
Hospitals
Drugstores
Others
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Oncology Immuno Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Oncology Immuno Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oncology Immuno Drug sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
The global Oncology Immuno Drug market is projected to grow from US$ 2365 million in 2024 to US$ 3807.5 million by 2030, at a Compound Annual Growth Rate (CAGR) of 8.3% during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Oncology Immuno Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Oncology Immuno Drug, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Oncology Immuno Drug, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Oncology Immuno Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Oncology Immuno Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Oncology Immuno Drug sales, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Roche AG
AstraZeneca
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
Merck KGaA
Segment by Type
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Other
Segment by Application
Hospitals
Drugstores
Others
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Oncology Immuno Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Oncology Immuno Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oncology Immuno Drug sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Oncology Immuno Drug Product Introduction
1.2 Market by Type
1.2.1 Global Oncology Immuno Drug Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Cytokine-Based Immunotherapy
1.2.4 Cancer Vaccines
1.2.5 CAR-T Cell Therapy
1.2.6 Other
1.3 Market by Application
1.3.1 Global Oncology Immuno Drug Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Oncology Immuno Drug Sales Estimates and Forecasts 2019-2030
2.2 Global Oncology Immuno Drug Revenue by Region
2.2.1 Global Oncology Immuno Drug Revenue by Region: 2019 VS 2023 VS 2030
2.2.2 Global Oncology Immuno Drug Revenue by Region (2019-2024)
2.2.3 Global Oncology Immuno Drug Revenue by Region (2025-2030)
2.2.4 Global Oncology Immuno Drug Revenue Market Share by Region (2019-2030)
2.3 Global Oncology Immuno Drug Sales Estimates and Forecasts 2019-2030
2.4 Global Oncology Immuno Drug Sales by Region
2.4.1 Global Oncology Immuno Drug Sales by Region: 2019 VS 2023 VS 2030
2.4.2 Global Oncology Immuno Drug Sales by Region (2019-2024)
2.4.3 Global Oncology Immuno Drug Sales by Region (2025-2030)
2.4.4 Global Oncology Immuno Drug Sales Market Share by Region (2019-2030)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Oncology Immuno Drug Sales by Manufacturers
3.1.1 Global Oncology Immuno Drug Sales by Manufacturers (2019-2024)
3.1.2 Global Oncology Immuno Drug Sales Market Share by Manufacturers (2019-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Oncology Immuno Drug in 2023
3.2 Global Oncology Immuno Drug Revenue by Manufacturers
3.2.1 Global Oncology Immuno Drug Revenue by Manufacturers (2019-2024)
3.2.2 Global Oncology Immuno Drug Revenue Market Share by Manufacturers (2019-2024)
3.2.3 Global Top 10 and Top 5 Companies by Oncology Immuno Drug Revenue in 2023
3.3 Global Key Players of Oncology Immuno Drug, Industry Ranking, 2022 VS 2023 VS 2024
3.4 Global Oncology Immuno Drug Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Oncology Immuno Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Oncology Immuno Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Oncology Immuno Drug, Product Offered and Application
3.8 Global Key Manufacturers of Oncology Immuno Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Oncology Immuno Drug Sales by Type
4.1.1 Global Oncology Immuno Drug Historical Sales by Type (2019-2024)
4.1.2 Global Oncology Immuno Drug Forecasted Sales by Type (2025-2030)
4.1.3 Global Oncology Immuno Drug Sales Market Share by Type (2019-2030)
4.2 Global Oncology Immuno Drug Revenue by Type
4.2.1 Global Oncology Immuno Drug Historical Revenue by Type (2019-2024)
4.2.2 Global Oncology Immuno Drug Forecasted Revenue by Type (2025-2030)
4.2.3 Global Oncology Immuno Drug Revenue Market Share by Type (2019-2030)
4.3 Global Oncology Immuno Drug Price by Type
4.3.1 Global Oncology Immuno Drug Price by Type (2019-2024)
4.3.2 Global Oncology Immuno Drug Price Forecast by Type (2025-2030)
5 Market Size by Application
5.1 Global Oncology Immuno Drug Sales by Application
5.1.1 Global Oncology Immuno Drug Historical Sales by Application (2019-2024)
5.1.2 Global Oncology Immuno Drug Forecasted Sales by Application (2025-2030)
5.1.3 Global Oncology Immuno Drug Sales Market Share by Application (2019-2030)
5.2 Global Oncology Immuno Drug Revenue by Application
5.2.1 Global Oncology Immuno Drug Historical Revenue by Application (2019-2024)
5.2.2 Global Oncology Immuno Drug Forecasted Revenue by Application (2025-2030)
5.2.3 Global Oncology Immuno Drug Revenue Market Share by Application (2019-2030)
5.3 Global Oncology Immuno Drug Price by Application
5.3.1 Global Oncology Immuno Drug Price by Application (2019-2024)
5.3.2 Global Oncology Immuno Drug Price Forecast by Application (2025-2030)
6 US & Canada
6.1 US & Canada Oncology Immuno Drug Market Size by Type
6.1.1 US & Canada Oncology Immuno Drug Sales by Type (2019-2030)
6.1.2 US & Canada Oncology Immuno Drug Revenue by Type (2019-2030)
6.2 US & Canada Oncology Immuno Drug Market Size by Application
6.2.1 US & Canada Oncology Immuno Drug Sales by Application (2019-2030)
6.2.2 US & Canada Oncology Immuno Drug Revenue by Application (2019-2030)
6.3 US & Canada Oncology Immuno Drug Market Size by Country
6.3.1 US & Canada Oncology Immuno Drug Revenue by Country: 2019 VS 2023 VS 2030
6.3.2 US & Canada Oncology Immuno Drug Sales by Country (2019-2030)
6.3.3 US & Canada Oncology Immuno Drug Revenue by Country (2019-2030)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Oncology Immuno Drug Market Size by Type
7.1.1 Europe Oncology Immuno Drug Sales by Type (2019-2030)
7.1.2 Europe Oncology Immuno Drug Revenue by Type (2019-2030)
7.2 Europe Oncology Immuno Drug Market Size by Application
7.2.1 Europe Oncology Immuno Drug Sales by Application (2019-2030)
7.2.2 Europe Oncology Immuno Drug Revenue by Application (2019-2030)
7.3 Europe Oncology Immuno Drug Market Size by Country
7.3.1 Europe Oncology Immuno Drug Revenue by Country: 2019 VS 2023 VS 2030
7.3.2 Europe Oncology Immuno Drug Sales by Country (2019-2030)
7.3.3 Europe Oncology Immuno Drug Revenue by Country (2019-2030)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Oncology Immuno Drug Market Size
8.1.1 China Oncology Immuno Drug Sales (2019-2030)
8.1.2 China Oncology Immuno Drug Revenue (2019-2030)
8.2 China Oncology Immuno Drug Market Size by Application
8.2.1 China Oncology Immuno Drug Sales by Application (2019-2030)
8.2.2 China Oncology Immuno Drug Revenue by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Oncology Immuno Drug Market Size by Type
9.1.1 Asia Oncology Immuno Drug Sales by Type (2019-2030)
9.1.2 Asia Oncology Immuno Drug Revenue by Type (2019-2030)
9.2 Asia Oncology Immuno Drug Market Size by Application
9.2.1 Asia Oncology Immuno Drug Sales by Application (2019-2030)
9.2.2 Asia Oncology Immuno Drug Revenue by Application (2019-2030)
9.3 Asia Oncology Immuno Drug Sales by Region
9.3.1 Asia Oncology Immuno Drug Revenue by Region: 2019 VS 2023 VS 2030
9.3.2 Asia Oncology Immuno Drug Revenue by Region (2019-2030)
9.3.3 Asia Oncology Immuno Drug Sales by Region (2019-2030)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Oncology Immuno Drug Market Size by Type
10.1.1 Middle East, Africa and Latin America Oncology Immuno Drug Sales by Type (2019-2030)
10.1.2 Middle East, Africa and Latin America Oncology Immuno Drug Revenue by Type (2019-2030)
10.2 Middle East, Africa and Latin America Oncology Immuno Drug Market Size by Application
10.2.1 Middle East, Africa and Latin America Oncology Immuno Drug Sales by Application (2019-2030)
10.2.2 Middle East, Africa and Latin America Oncology Immuno Drug Revenue by Application (2019-2030)
10.3 Middle East, Africa and Latin America Oncology Immuno Drug Sales by Country
10.3.1 Middle East, Africa and Latin America Oncology Immuno Drug Revenue by Country: 2019 VS 2023 VS 2030
10.3.2 Middle East, Africa and Latin America Oncology Immuno Drug Revenue by Country (2019-2030)
10.3.3 Middle East, Africa and Latin America Oncology Immuno Drug Sales by Country (2019-2030)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Information
11.1.2 Bristol-Myers Squibb Overview
11.1.3 Bristol-Myers Squibb Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.1.4 Bristol-Myers Squibb Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Bristol-Myers Squibb Recent Developments
11.2 Merck & Co
11.2.1 Merck & Co Company Information
11.2.2 Merck & Co Overview
11.2.3 Merck & Co Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.2.4 Merck & Co Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Merck & Co Recent Developments
11.3 Roche AG
11.3.1 Roche AG Company Information
11.3.2 Roche AG Overview
11.3.3 Roche AG Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.3.4 Roche AG Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Roche AG Recent Developments
11.4 AstraZeneca
11.4.1 AstraZeneca Company Information
11.4.2 AstraZeneca Overview
11.4.3 AstraZeneca Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.4.4 AstraZeneca Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 AstraZeneca Recent Developments
11.5 Sanofi S.A.
11.5.1 Sanofi S.A. Company Information
11.5.2 Sanofi S.A. Overview
11.5.3 Sanofi S.A. Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.5.4 Sanofi S.A. Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Sanofi S.A. Recent Developments
11.6 Dendreon Pharmaceuticals
11.6.1 Dendreon Pharmaceuticals Company Information
11.6.2 Dendreon Pharmaceuticals Overview
11.6.3 Dendreon Pharmaceuticals Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.6.4 Dendreon Pharmaceuticals Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Dendreon Pharmaceuticals Recent Developments
11.7 Novartis
11.7.1 Novartis Company Information
11.7.2 Novartis Overview
11.7.3 Novartis Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.7.4 Novartis Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Novartis Recent Developments
11.8 Gilead Sciences Inc.
11.8.1 Gilead Sciences Inc. Company Information
11.8.2 Gilead Sciences Inc. Overview
11.8.3 Gilead Sciences Inc. Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.8.4 Gilead Sciences Inc. Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Gilead Sciences Inc. Recent Developments
11.9 Merck KGaA
11.9.1 Merck KGaA Company Information
11.9.2 Merck KGaA Overview
11.9.3 Merck KGaA Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.9.4 Merck KGaA Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Merck KGaA Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Oncology Immuno Drug Industry Chain Analysis
12.2 Oncology Immuno Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Oncology Immuno Drug Production Mode & Process
12.4 Oncology Immuno Drug Sales and Marketing
12.4.1 Oncology Immuno Drug Sales Channels
12.4.2 Oncology Immuno Drug Distributors
12.5 Oncology Immuno Drug Customers
13 Market Dynamics
13.1 Oncology Immuno Drug Industry Trends
13.2 Oncology Immuno Drug Market Drivers
13.3 Oncology Immuno Drug Market Challenges
13.4 Oncology Immuno Drug Market Restraints
14 Key Findings in The Global Oncology Immuno Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
1.1 Oncology Immuno Drug Product Introduction
1.2 Market by Type
1.2.1 Global Oncology Immuno Drug Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Cytokine-Based Immunotherapy
1.2.4 Cancer Vaccines
1.2.5 CAR-T Cell Therapy
1.2.6 Other
1.3 Market by Application
1.3.1 Global Oncology Immuno Drug Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Oncology Immuno Drug Sales Estimates and Forecasts 2019-2030
2.2 Global Oncology Immuno Drug Revenue by Region
2.2.1 Global Oncology Immuno Drug Revenue by Region: 2019 VS 2023 VS 2030
2.2.2 Global Oncology Immuno Drug Revenue by Region (2019-2024)
2.2.3 Global Oncology Immuno Drug Revenue by Region (2025-2030)
2.2.4 Global Oncology Immuno Drug Revenue Market Share by Region (2019-2030)
2.3 Global Oncology Immuno Drug Sales Estimates and Forecasts 2019-2030
2.4 Global Oncology Immuno Drug Sales by Region
2.4.1 Global Oncology Immuno Drug Sales by Region: 2019 VS 2023 VS 2030
2.4.2 Global Oncology Immuno Drug Sales by Region (2019-2024)
2.4.3 Global Oncology Immuno Drug Sales by Region (2025-2030)
2.4.4 Global Oncology Immuno Drug Sales Market Share by Region (2019-2030)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Oncology Immuno Drug Sales by Manufacturers
3.1.1 Global Oncology Immuno Drug Sales by Manufacturers (2019-2024)
3.1.2 Global Oncology Immuno Drug Sales Market Share by Manufacturers (2019-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Oncology Immuno Drug in 2023
3.2 Global Oncology Immuno Drug Revenue by Manufacturers
3.2.1 Global Oncology Immuno Drug Revenue by Manufacturers (2019-2024)
3.2.2 Global Oncology Immuno Drug Revenue Market Share by Manufacturers (2019-2024)
3.2.3 Global Top 10 and Top 5 Companies by Oncology Immuno Drug Revenue in 2023
3.3 Global Key Players of Oncology Immuno Drug, Industry Ranking, 2022 VS 2023 VS 2024
3.4 Global Oncology Immuno Drug Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Oncology Immuno Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Oncology Immuno Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Oncology Immuno Drug, Product Offered and Application
3.8 Global Key Manufacturers of Oncology Immuno Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Oncology Immuno Drug Sales by Type
4.1.1 Global Oncology Immuno Drug Historical Sales by Type (2019-2024)
4.1.2 Global Oncology Immuno Drug Forecasted Sales by Type (2025-2030)
4.1.3 Global Oncology Immuno Drug Sales Market Share by Type (2019-2030)
4.2 Global Oncology Immuno Drug Revenue by Type
4.2.1 Global Oncology Immuno Drug Historical Revenue by Type (2019-2024)
4.2.2 Global Oncology Immuno Drug Forecasted Revenue by Type (2025-2030)
4.2.3 Global Oncology Immuno Drug Revenue Market Share by Type (2019-2030)
4.3 Global Oncology Immuno Drug Price by Type
4.3.1 Global Oncology Immuno Drug Price by Type (2019-2024)
4.3.2 Global Oncology Immuno Drug Price Forecast by Type (2025-2030)
5 Market Size by Application
5.1 Global Oncology Immuno Drug Sales by Application
5.1.1 Global Oncology Immuno Drug Historical Sales by Application (2019-2024)
5.1.2 Global Oncology Immuno Drug Forecasted Sales by Application (2025-2030)
5.1.3 Global Oncology Immuno Drug Sales Market Share by Application (2019-2030)
5.2 Global Oncology Immuno Drug Revenue by Application
5.2.1 Global Oncology Immuno Drug Historical Revenue by Application (2019-2024)
5.2.2 Global Oncology Immuno Drug Forecasted Revenue by Application (2025-2030)
5.2.3 Global Oncology Immuno Drug Revenue Market Share by Application (2019-2030)
5.3 Global Oncology Immuno Drug Price by Application
5.3.1 Global Oncology Immuno Drug Price by Application (2019-2024)
5.3.2 Global Oncology Immuno Drug Price Forecast by Application (2025-2030)
6 US & Canada
6.1 US & Canada Oncology Immuno Drug Market Size by Type
6.1.1 US & Canada Oncology Immuno Drug Sales by Type (2019-2030)
6.1.2 US & Canada Oncology Immuno Drug Revenue by Type (2019-2030)
6.2 US & Canada Oncology Immuno Drug Market Size by Application
6.2.1 US & Canada Oncology Immuno Drug Sales by Application (2019-2030)
6.2.2 US & Canada Oncology Immuno Drug Revenue by Application (2019-2030)
6.3 US & Canada Oncology Immuno Drug Market Size by Country
6.3.1 US & Canada Oncology Immuno Drug Revenue by Country: 2019 VS 2023 VS 2030
6.3.2 US & Canada Oncology Immuno Drug Sales by Country (2019-2030)
6.3.3 US & Canada Oncology Immuno Drug Revenue by Country (2019-2030)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Oncology Immuno Drug Market Size by Type
7.1.1 Europe Oncology Immuno Drug Sales by Type (2019-2030)
7.1.2 Europe Oncology Immuno Drug Revenue by Type (2019-2030)
7.2 Europe Oncology Immuno Drug Market Size by Application
7.2.1 Europe Oncology Immuno Drug Sales by Application (2019-2030)
7.2.2 Europe Oncology Immuno Drug Revenue by Application (2019-2030)
7.3 Europe Oncology Immuno Drug Market Size by Country
7.3.1 Europe Oncology Immuno Drug Revenue by Country: 2019 VS 2023 VS 2030
7.3.2 Europe Oncology Immuno Drug Sales by Country (2019-2030)
7.3.3 Europe Oncology Immuno Drug Revenue by Country (2019-2030)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Oncology Immuno Drug Market Size
8.1.1 China Oncology Immuno Drug Sales (2019-2030)
8.1.2 China Oncology Immuno Drug Revenue (2019-2030)
8.2 China Oncology Immuno Drug Market Size by Application
8.2.1 China Oncology Immuno Drug Sales by Application (2019-2030)
8.2.2 China Oncology Immuno Drug Revenue by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Oncology Immuno Drug Market Size by Type
9.1.1 Asia Oncology Immuno Drug Sales by Type (2019-2030)
9.1.2 Asia Oncology Immuno Drug Revenue by Type (2019-2030)
9.2 Asia Oncology Immuno Drug Market Size by Application
9.2.1 Asia Oncology Immuno Drug Sales by Application (2019-2030)
9.2.2 Asia Oncology Immuno Drug Revenue by Application (2019-2030)
9.3 Asia Oncology Immuno Drug Sales by Region
9.3.1 Asia Oncology Immuno Drug Revenue by Region: 2019 VS 2023 VS 2030
9.3.2 Asia Oncology Immuno Drug Revenue by Region (2019-2030)
9.3.3 Asia Oncology Immuno Drug Sales by Region (2019-2030)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Oncology Immuno Drug Market Size by Type
10.1.1 Middle East, Africa and Latin America Oncology Immuno Drug Sales by Type (2019-2030)
10.1.2 Middle East, Africa and Latin America Oncology Immuno Drug Revenue by Type (2019-2030)
10.2 Middle East, Africa and Latin America Oncology Immuno Drug Market Size by Application
10.2.1 Middle East, Africa and Latin America Oncology Immuno Drug Sales by Application (2019-2030)
10.2.2 Middle East, Africa and Latin America Oncology Immuno Drug Revenue by Application (2019-2030)
10.3 Middle East, Africa and Latin America Oncology Immuno Drug Sales by Country
10.3.1 Middle East, Africa and Latin America Oncology Immuno Drug Revenue by Country: 2019 VS 2023 VS 2030
10.3.2 Middle East, Africa and Latin America Oncology Immuno Drug Revenue by Country (2019-2030)
10.3.3 Middle East, Africa and Latin America Oncology Immuno Drug Sales by Country (2019-2030)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Information
11.1.2 Bristol-Myers Squibb Overview
11.1.3 Bristol-Myers Squibb Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.1.4 Bristol-Myers Squibb Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Bristol-Myers Squibb Recent Developments
11.2 Merck & Co
11.2.1 Merck & Co Company Information
11.2.2 Merck & Co Overview
11.2.3 Merck & Co Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.2.4 Merck & Co Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Merck & Co Recent Developments
11.3 Roche AG
11.3.1 Roche AG Company Information
11.3.2 Roche AG Overview
11.3.3 Roche AG Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.3.4 Roche AG Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Roche AG Recent Developments
11.4 AstraZeneca
11.4.1 AstraZeneca Company Information
11.4.2 AstraZeneca Overview
11.4.3 AstraZeneca Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.4.4 AstraZeneca Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 AstraZeneca Recent Developments
11.5 Sanofi S.A.
11.5.1 Sanofi S.A. Company Information
11.5.2 Sanofi S.A. Overview
11.5.3 Sanofi S.A. Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.5.4 Sanofi S.A. Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Sanofi S.A. Recent Developments
11.6 Dendreon Pharmaceuticals
11.6.1 Dendreon Pharmaceuticals Company Information
11.6.2 Dendreon Pharmaceuticals Overview
11.6.3 Dendreon Pharmaceuticals Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.6.4 Dendreon Pharmaceuticals Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Dendreon Pharmaceuticals Recent Developments
11.7 Novartis
11.7.1 Novartis Company Information
11.7.2 Novartis Overview
11.7.3 Novartis Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.7.4 Novartis Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Novartis Recent Developments
11.8 Gilead Sciences Inc.
11.8.1 Gilead Sciences Inc. Company Information
11.8.2 Gilead Sciences Inc. Overview
11.8.3 Gilead Sciences Inc. Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.8.4 Gilead Sciences Inc. Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Gilead Sciences Inc. Recent Developments
11.9 Merck KGaA
11.9.1 Merck KGaA Company Information
11.9.2 Merck KGaA Overview
11.9.3 Merck KGaA Oncology Immuno Drug Sales, Price, Revenue and Gross Margin (2019-2024)
11.9.4 Merck KGaA Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Merck KGaA Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Oncology Immuno Drug Industry Chain Analysis
12.2 Oncology Immuno Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Oncology Immuno Drug Production Mode & Process
12.4 Oncology Immuno Drug Sales and Marketing
12.4.1 Oncology Immuno Drug Sales Channels
12.4.2 Oncology Immuno Drug Distributors
12.5 Oncology Immuno Drug Customers
13 Market Dynamics
13.1 Oncology Immuno Drug Industry Trends
13.2 Oncology Immuno Drug Market Drivers
13.3 Oncology Immuno Drug Market Challenges
13.4 Oncology Immuno Drug Market Restraints
14 Key Findings in The Global Oncology Immuno Drug Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Oncology Immuno Drug Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Table 2. Major Manufacturers of Immune Checkpoint Inhibitors
Table 3. Major Manufacturers of Cytokine-Based Immunotherapy
Table 4. Major Manufacturers of Cancer Vaccines
Table 5. Major Manufacturers of CAR-T Cell Therapy
Table 6. Major Manufacturers of Other
Table 7. Global Oncology Immuno Drug Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Table 8. Global Oncology Immuno Drug Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 9. Global Oncology Immuno Drug Revenue by Region (2019-2024) & (US$ Million)
Table 10. Global Oncology Immuno Drug Revenue by Region (2025-2030) & (US$ Million)
Table 11. Global Oncology Immuno Drug Revenue Market Share by Region (2019-2024)
Table 12. Global Oncology Immuno Drug Revenue Market Share by Region (2025-2030)
Table 13. Global Oncology Immuno Drug Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Oncology Immuno Drug Sales by Region (2019-2024) & (K Units)
Table 15. Global Oncology Immuno Drug Sales by Region (2025-2030) & (K Units)
Table 16. Global Oncology Immuno Drug Sales Market Share by Region (2019-2024)
Table 17. Global Oncology Immuno Drug Sales Market Share by Region (2025-2030)
Table 18. Global Oncology Immuno Drug Sales by Manufacturers (2019-2024) & (K Units)
Table 19. Global Oncology Immuno Drug Sales Share by Manufacturers (2019-2024)
Table 20. Global Oncology Immuno Drug Revenue by Manufacturers (2019-2024) & (US$ Million)
Table 21. Global Oncology Immuno Drug Revenue Share by Manufacturers (2019-2024)
Table 22. Global Key Players of Oncology Immuno Drug, Industry Ranking, 2022 VS 2023 VS 2024
Table 23. Oncology Immuno Drug Price by Manufacturers 2019-2024 (US$/Unit)
Table 24. Global Oncology Immuno Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 25. Global Oncology Immuno Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Immuno Drug as of 2023)
Table 26. Global Key Manufacturers of Oncology Immuno Drug, Manufacturing Base Distribution and Headquarters
Table 27. Global Key Manufacturers of Oncology Immuno Drug, Product Offered and Application
Table 28. Global Key Manufacturers of Oncology Immuno Drug, Date of Enter into This Industry
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Oncology Immuno Drug Sales by Type (2019-2024) & (K Units)
Table 31. Global Oncology Immuno Drug Sales by Type (2025-2030) & (K Units)
Table 32. Global Oncology Immuno Drug Sales Share by Type (2019-2024)
Table 33. Global Oncology Immuno Drug Sales Share by Type (2025-2030)
Table 34. Global Oncology Immuno Drug Revenue by Type (2019-2024) & (US$ Million)
Table 35. Global Oncology Immuno Drug Revenue by Type (2025-2030) & (US$ Million)
Table 36. Global Oncology Immuno Drug Revenue Share by Type (2019-2024)
Table 37. Global Oncology Immuno Drug Revenue Share by Type (2025-2030)
Table 38. Oncology Immuno Drug Price by Type (2019-2024) & (US$/Unit)
Table 39. Global Oncology Immuno Drug Price Forecast by Type (2025-2030) & (US$/Unit)
Table 40. Global Oncology Immuno Drug Sales by Application (2019-2024) & (K Units)
Table 41. Global Oncology Immuno Drug Sales by Application (2025-2030) & (K Units)
Table 42. Global Oncology Immuno Drug Sales Share by Application (2019-2024)
Table 43. Global Oncology Immuno Drug Sales Share by Application (2025-2030)
Table 44. Global Oncology Immuno Drug Revenue by Application (2019-2024) & (US$ Million)
Table 45. Global Oncology Immuno Drug Revenue by Application (2025-2030) & (US$ Million)
Table 46. Global Oncology Immuno Drug Revenue Share by Application (2019-2024)
Table 47. Global Oncology Immuno Drug Revenue Share by Application (2025-2030)
Table 48. Oncology Immuno Drug Price by Application (2019-2024) & (US$/Unit)
Table 49. Global Oncology Immuno Drug Price Forecast by Application (2025-2030) & (US$/Unit)
Table 50. US & Canada Oncology Immuno Drug Sales by Type (2019-2024) & (K Units)
Table 51. US & Canada Oncology Immuno Drug Sales by Type (2025-2030) & (K Units)
Table 52. US & Canada Oncology Immuno Drug Revenue by Type (2019-2024) & (US$ Million)
Table 53. US & Canada Oncology Immuno Drug Revenue by Type (2025-2030) & (US$ Million)
Table 54. US & Canada Oncology Immuno Drug Sales by Application (2019-2024) & (K Units)
Table 55. US & Canada Oncology Immuno Drug Sales by Application (2025-2030) & (K Units)
Table 56. US & Canada Oncology Immuno Drug Revenue by Application (2019-2024) & (US$ Million)
Table 57. US & Canada Oncology Immuno Drug Revenue by Application (2025-2030) & (US$ Million)
Table 58. US & Canada Oncology Immuno Drug Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 59. US & Canada Oncology Immuno Drug Revenue by Country (2019-2024) & (US$ Million)
Table 60. US & Canada Oncology Immuno Drug Revenue by Country (2025-2030) & (US$ Million)
Table 61. US & Canada Oncology Immuno Drug Sales by Country (2019-2024) & (K Units)
Table 62. US & Canada Oncology Immuno Drug Sales by Country (2025-2030) & (K Units)
Table 63. Europe Oncology Immuno Drug Sales by Type (2019-2024) & (K Units)
Table 64. Europe Oncology Immuno Drug Sales by Type (2025-2030) & (K Units)
Table 65. Europe Oncology Immuno Drug Revenue by Type (2019-2024) & (US$ Million)
Table 66. Europe Oncology Immuno Drug Revenue by Type (2025-2030) & (US$ Million)
Table 67. Europe Oncology Immuno Drug Sales by Application (2019-2024) & (K Units)
Table 68. Europe Oncology Immuno Drug Sales by Application (2025-2030) & (K Units)
Table 69. Europe Oncology Immuno Drug Revenue by Application (2019-2024) & (US$ Million)
Table 70. Europe Oncology Immuno Drug Revenue by Application (2025-2030) & (US$ Million)
Table 71. Europe Oncology Immuno Drug Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 72. Europe Oncology Immuno Drug Revenue by Country (2019-2024) & (US$ Million)
Table 73. Europe Oncology Immuno Drug Revenue by Country (2025-2030) & (US$ Million)
Table 74. Europe Oncology Immuno Drug Sales by Country (2019-2024) & (K Units)
Table 75. Europe Oncology Immuno Drug Sales by Country (2025-2030) & (K Units)
Table 76. China Oncology Immuno Drug Sales by Type (2019-2024) & (K Units)
Table 77. China Oncology Immuno Drug Sales by Type (2025-2030) & (K Units)
Table 78. China Oncology Immuno Drug Revenue by Type (2019-2024) & (US$ Million)
Table 79. China Oncology Immuno Drug Revenue by Type (2025-2030) & (US$ Million)
Table 80. China Oncology Immuno Drug Sales by Application (2019-2024) & (K Units)
Table 81. China Oncology Immuno Drug Sales by Application (2025-2030) & (K Units)
Table 82. China Oncology Immuno Drug Revenue by Application (2019-2024) & (US$ Million)
Table 83. China Oncology Immuno Drug Revenue by Application (2025-2030) & (US$ Million)
Table 84. Asia Oncology Immuno Drug Sales by Type (2019-2024) & (K Units)
Table 85. Asia Oncology Immuno Drug Sales by Type (2025-2030) & (K Units)
Table 86. Asia Oncology Immuno Drug Revenue by Type (2019-2024) & (US$ Million)
Table 87. Asia Oncology Immuno Drug Revenue by Type (2025-2030) & (US$ Million)
Table 88. Asia Oncology Immuno Drug Sales by Application (2019-2024) & (K Units)
Table 89. Asia Oncology Immuno Drug Sales by Application (2025-2030) & (K Units)
Table 90. Asia Oncology Immuno Drug Revenue by Application (2019-2024) & (US$ Million)
Table 91. Asia Oncology Immuno Drug Revenue by Application (2025-2030) & (US$ Million)
Table 92. Asia Oncology Immuno Drug Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 93. Asia Oncology Immuno Drug Revenue by Region (2019-2024) & (US$ Million)
Table 94. Asia Oncology Immuno Drug Revenue by Region (2025-2030) & (US$ Million)
Table 95. Asia Oncology Immuno Drug Sales by Region (2019-2024) & (K Units)
Table 96. Asia Oncology Immuno Drug Sales by Region (2025-2030) & (K Units)
Table 97. Middle East, Africa and Latin America Oncology Immuno Drug Sales by Type (2019-2024) & (K Units)
Table 98. Middle East, Africa and Latin America Oncology Immuno Drug Sales by Type (2025-2030) & (K Units)
Table 99. Middle East, Africa and Latin America Oncology Immuno Drug Revenue by Type (2019-2024) & (US$ Million)
Table 100. Middle East, Africa and Latin America Oncology Immuno Drug Revenue by Type (2025-2030) & (US$ Million)
Table 101. Middle East, Africa and Latin America Oncology Immuno Drug Sales by Application (2019-2024) & (K Units)
Table 102. Middle East, Africa and Latin America Oncology Immuno Drug Sales by Application (2025-2030) & (K Units)
Table 103. Middle East, Africa and Latin America Oncology Immuno Drug Revenue by Application (2019-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Oncology Immuno Drug Revenue by Application (2025-2030) & (US$ Million)
Table 105. Middle East, Africa and Latin America Oncology Immuno Drug Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 106. Middle East, Africa and Latin America Oncology Immuno Drug Revenue by Country (2019-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America Oncology Immuno Drug Revenue by Country (2025-2030) & (US$ Million)
Table 108. Middle East, Africa and Latin America Oncology Immuno Drug Sales by Country (2019-2024) & (K Units)
Table 109. Middle East, Africa and Latin America Oncology Immuno Drug Sales by Country (2025-2030) & (K Units)
Table 110. Bristol-Myers Squibb Company Information
Table 111. Bristol-Myers Squibb Description and Major Businesses
Table 112. Bristol-Myers Squibb Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Bristol-Myers Squibb Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 114. Bristol-Myers Squibb Recent Developments
Table 115. Merck & Co Company Information
Table 116. Merck & Co Description and Major Businesses
Table 117. Merck & Co Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Merck & Co Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 119. Merck & Co Recent Developments
Table 120. Roche AG Company Information
Table 121. Roche AG Description and Major Businesses
Table 122. Roche AG Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Roche AG Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 124. Roche AG Recent Developments
Table 125. AstraZeneca Company Information
Table 126. AstraZeneca Description and Major Businesses
Table 127. AstraZeneca Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. AstraZeneca Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 129. AstraZeneca Recent Developments
Table 130. Sanofi S.A. Company Information
Table 131. Sanofi S.A. Description and Major Businesses
Table 132. Sanofi S.A. Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. Sanofi S.A. Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 134. Sanofi S.A. Recent Developments
Table 135. Dendreon Pharmaceuticals Company Information
Table 136. Dendreon Pharmaceuticals Description and Major Businesses
Table 137. Dendreon Pharmaceuticals Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138. Dendreon Pharmaceuticals Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 139. Dendreon Pharmaceuticals Recent Developments
Table 140. Novartis Company Information
Table 141. Novartis Description and Major Businesses
Table 142. Novartis Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 143. Novartis Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 144. Novartis Recent Developments
Table 145. Gilead Sciences Inc. Company Information
Table 146. Gilead Sciences Inc. Description and Major Businesses
Table 147. Gilead Sciences Inc. Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 148. Gilead Sciences Inc. Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 149. Gilead Sciences Inc. Recent Developments
Table 150. Merck KGaA Company Information
Table 151. Merck KGaA Description and Major Businesses
Table 152. Merck KGaA Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 153. Merck KGaA Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 154. Merck KGaA Recent Developments
Table 155. Key Raw Materials Lists
Table 156. Raw Materials Key Suppliers Lists
Table 157. Oncology Immuno Drug Distributors List
Table 158. Oncology Immuno Drug Customers List
Table 159. Oncology Immuno Drug Market Trends
Table 160. Oncology Immuno Drug Market Drivers
Table 161. Oncology Immuno Drug Market Challenges
Table 162. Oncology Immuno Drug Market Restraints
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources
List of Figures
Figure 1. Oncology Immuno Drug Product Picture
Figure 2. Global Oncology Immuno Drug Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Oncology Immuno Drug Market Share by Type in 2023 & 2030
Figure 4. Immune Checkpoint Inhibitors Product Picture
Figure 5. Cytokine-Based Immunotherapy Product Picture
Figure 6. Cancer Vaccines Product Picture
Figure 7. CAR-T Cell Therapy Product Picture
Figure 8. Other Product Picture
Figure 9. Global Oncology Immuno Drug Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Figure 10. Global Oncology Immuno Drug Market Share by Application in 2023 & 2030
Figure 11. Hospitals
Figure 12. Drugstores
Figure 13. Others
Figure 14. Oncology Immuno Drug Report Years Considered
Figure 15. Global Oncology Immuno Drug Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Oncology Immuno Drug Revenue 2019-2030 (US$ Million)
Figure 17. Global Oncology Immuno Drug Revenue Market Share by Region in Percentage: 2023 Versus 2030
Figure 18. Global Oncology Immuno Drug Revenue Market Share by Region (2019-2030)
Figure 19. Global Oncology Immuno Drug Sales 2019-2030 ((K Units)
Figure 20. Global Oncology Immuno Drug Sales Market Share by Region (2019-2030)
Figure 21. US & Canada Oncology Immuno Drug Sales YoY (2019-2030) & (K Units)
Figure 22. US & Canada Oncology Immuno Drug Revenue YoY (2019-2030) & (US$ Million)
Figure 23. Europe Oncology Immuno Drug Sales YoY (2019-2030) & (K Units)
Figure 24. Europe Oncology Immuno Drug Revenue YoY (2019-2030) & (US$ Million)
Figure 25. China Oncology Immuno Drug Sales YoY (2019-2030) & (K Units)
Figure 26. China Oncology Immuno Drug Revenue YoY (2019-2030) & (US$ Million)
Figure 27. Asia (excluding China) Oncology Immuno Drug Sales YoY (2019-2030) & (K Units)
Figure 28. Asia (excluding China) Oncology Immuno Drug Revenue YoY (2019-2030) & (US$ Million)
Figure 29. Middle East, Africa and Latin America Oncology Immuno Drug Sales YoY (2019-2030) & (K Units)
Figure 30. Middle East, Africa and Latin America Oncology Immuno Drug Revenue YoY (2019-2030) & (US$ Million)
Figure 31. The Oncology Immuno Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023
Figure 32. The Top 5 and 10 Largest Manufacturers of Oncology Immuno Drug in the World: Market Share by Oncology Immuno Drug Revenue in 2023
Figure 33. Global Oncology Immuno Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 34. Global Oncology Immuno Drug Sales Market Share by Type (2019-2030)
Figure 35. Global Oncology Immuno Drug Revenue Market Share by Type (2019-2030)
Figure 36. Global Oncology Immuno Drug Sales Market Share by Application (2019-2030)
Figure 37. Global Oncology Immuno Drug Revenue Market Share by Application (2019-2030)
Figure 38. US & Canada Oncology Immuno Drug Sales Market Share by Type (2019-2030)
Figure 39. US & Canada Oncology Immuno Drug Revenue Market Share by Type (2019-2030)
Figure 40. US & Canada Oncology Immuno Drug Sales Market Share by Application (2019-2030)
Figure 41. US & Canada Oncology Immuno Drug Revenue Market Share by Application (2019-2030)
Figure 42. US & Canada Oncology Immuno Drug Revenue Share by Country (2019-2030)
Figure 43. US & Canada Oncology Immuno Drug Sales Share by Country (2019-2030)
Figure 44. U.S. Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 45. Canada Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 46. Europe Oncology Immuno Drug Sales Market Share by Type (2019-2030)
Figure 47. Europe Oncology Immuno Drug Revenue Market Share by Type (2019-2030)
Figure 48. Europe Oncology Immuno Drug Sales Market Share by Application (2019-2030)
Figure 49. Europe Oncology Immuno Drug Revenue Market Share by Application (2019-2030)
Figure 50. Europe Oncology Immuno Drug Revenue Share by Country (2019-2030)
Figure 51. Europe Oncology Immuno Drug Sales Share by Country (2019-2030)
Figure 52. Germany Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 53. France Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 54. U.K. Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 55. Italy Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 56. Russia Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 57. China Oncology Immuno Drug Sales Market Share by Type (2019-2030)
Figure 58. China Oncology Immuno Drug Revenue Market Share by Type (2019-2030)
Figure 59. China Oncology Immuno Drug Sales Market Share by Application (2019-2030)
Figure 60. China Oncology Immuno Drug Revenue Market Share by Application (2019-2030)
Figure 61. Asia Oncology Immuno Drug Sales Market Share by Type (2019-2030)
Figure 62. Asia Oncology Immuno Drug Revenue Market Share by Type (2019-2030)
Figure 63. Asia Oncology Immuno Drug Sales Market Share by Application (2019-2030)
Figure 64. Asia Oncology Immuno Drug Revenue Market Share by Application (2019-2030)
Figure 65. Asia Oncology Immuno Drug Revenue Share by Region (2019-2030)
Figure 66. Asia Oncology Immuno Drug Sales Share by Region (2019-2030)
Figure 67. Japan Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 68. South Korea Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 69. China Taiwan Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 70. Southeast Asia Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 71. India Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 72. Middle East, Africa and Latin America Oncology Immuno Drug Sales Market Share by Type (2019-2030)
Figure 73. Middle East, Africa and Latin America Oncology Immuno Drug Revenue Market Share by Type (2019-2030)
Figure 74. Middle East, Africa and Latin America Oncology Immuno Drug Sales Market Share by Application (2019-2030)
Figure 75. Middle East, Africa and Latin America Oncology Immuno Drug Revenue Market Share by Application (2019-2030)
Figure 76. Middle East, Africa and Latin America Oncology Immuno Drug Revenue Share by Country (2019-2030)
Figure 77. Middle East, Africa and Latin America Oncology Immuno Drug Sales Share by Country (2019-2030)
Figure 78. Brazil Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 79. Mexico Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 80. Turkey Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 81. Israel Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 82. GCC Countries Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 83. Oncology Immuno Drug Value Chain
Figure 84. Oncology Immuno Drug Production Process
Figure 85. Channels of Distribution
Figure 86. Distributors Profiles
Figure 87. Bottom-up and Top-down Approaches for This Report
Figure 88. Data Triangulation
Figure 89. Key Executives Interviewed
Table 1. Global Oncology Immuno Drug Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Table 2. Major Manufacturers of Immune Checkpoint Inhibitors
Table 3. Major Manufacturers of Cytokine-Based Immunotherapy
Table 4. Major Manufacturers of Cancer Vaccines
Table 5. Major Manufacturers of CAR-T Cell Therapy
Table 6. Major Manufacturers of Other
Table 7. Global Oncology Immuno Drug Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Table 8. Global Oncology Immuno Drug Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 9. Global Oncology Immuno Drug Revenue by Region (2019-2024) & (US$ Million)
Table 10. Global Oncology Immuno Drug Revenue by Region (2025-2030) & (US$ Million)
Table 11. Global Oncology Immuno Drug Revenue Market Share by Region (2019-2024)
Table 12. Global Oncology Immuno Drug Revenue Market Share by Region (2025-2030)
Table 13. Global Oncology Immuno Drug Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Oncology Immuno Drug Sales by Region (2019-2024) & (K Units)
Table 15. Global Oncology Immuno Drug Sales by Region (2025-2030) & (K Units)
Table 16. Global Oncology Immuno Drug Sales Market Share by Region (2019-2024)
Table 17. Global Oncology Immuno Drug Sales Market Share by Region (2025-2030)
Table 18. Global Oncology Immuno Drug Sales by Manufacturers (2019-2024) & (K Units)
Table 19. Global Oncology Immuno Drug Sales Share by Manufacturers (2019-2024)
Table 20. Global Oncology Immuno Drug Revenue by Manufacturers (2019-2024) & (US$ Million)
Table 21. Global Oncology Immuno Drug Revenue Share by Manufacturers (2019-2024)
Table 22. Global Key Players of Oncology Immuno Drug, Industry Ranking, 2022 VS 2023 VS 2024
Table 23. Oncology Immuno Drug Price by Manufacturers 2019-2024 (US$/Unit)
Table 24. Global Oncology Immuno Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 25. Global Oncology Immuno Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Immuno Drug as of 2023)
Table 26. Global Key Manufacturers of Oncology Immuno Drug, Manufacturing Base Distribution and Headquarters
Table 27. Global Key Manufacturers of Oncology Immuno Drug, Product Offered and Application
Table 28. Global Key Manufacturers of Oncology Immuno Drug, Date of Enter into This Industry
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Oncology Immuno Drug Sales by Type (2019-2024) & (K Units)
Table 31. Global Oncology Immuno Drug Sales by Type (2025-2030) & (K Units)
Table 32. Global Oncology Immuno Drug Sales Share by Type (2019-2024)
Table 33. Global Oncology Immuno Drug Sales Share by Type (2025-2030)
Table 34. Global Oncology Immuno Drug Revenue by Type (2019-2024) & (US$ Million)
Table 35. Global Oncology Immuno Drug Revenue by Type (2025-2030) & (US$ Million)
Table 36. Global Oncology Immuno Drug Revenue Share by Type (2019-2024)
Table 37. Global Oncology Immuno Drug Revenue Share by Type (2025-2030)
Table 38. Oncology Immuno Drug Price by Type (2019-2024) & (US$/Unit)
Table 39. Global Oncology Immuno Drug Price Forecast by Type (2025-2030) & (US$/Unit)
Table 40. Global Oncology Immuno Drug Sales by Application (2019-2024) & (K Units)
Table 41. Global Oncology Immuno Drug Sales by Application (2025-2030) & (K Units)
Table 42. Global Oncology Immuno Drug Sales Share by Application (2019-2024)
Table 43. Global Oncology Immuno Drug Sales Share by Application (2025-2030)
Table 44. Global Oncology Immuno Drug Revenue by Application (2019-2024) & (US$ Million)
Table 45. Global Oncology Immuno Drug Revenue by Application (2025-2030) & (US$ Million)
Table 46. Global Oncology Immuno Drug Revenue Share by Application (2019-2024)
Table 47. Global Oncology Immuno Drug Revenue Share by Application (2025-2030)
Table 48. Oncology Immuno Drug Price by Application (2019-2024) & (US$/Unit)
Table 49. Global Oncology Immuno Drug Price Forecast by Application (2025-2030) & (US$/Unit)
Table 50. US & Canada Oncology Immuno Drug Sales by Type (2019-2024) & (K Units)
Table 51. US & Canada Oncology Immuno Drug Sales by Type (2025-2030) & (K Units)
Table 52. US & Canada Oncology Immuno Drug Revenue by Type (2019-2024) & (US$ Million)
Table 53. US & Canada Oncology Immuno Drug Revenue by Type (2025-2030) & (US$ Million)
Table 54. US & Canada Oncology Immuno Drug Sales by Application (2019-2024) & (K Units)
Table 55. US & Canada Oncology Immuno Drug Sales by Application (2025-2030) & (K Units)
Table 56. US & Canada Oncology Immuno Drug Revenue by Application (2019-2024) & (US$ Million)
Table 57. US & Canada Oncology Immuno Drug Revenue by Application (2025-2030) & (US$ Million)
Table 58. US & Canada Oncology Immuno Drug Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 59. US & Canada Oncology Immuno Drug Revenue by Country (2019-2024) & (US$ Million)
Table 60. US & Canada Oncology Immuno Drug Revenue by Country (2025-2030) & (US$ Million)
Table 61. US & Canada Oncology Immuno Drug Sales by Country (2019-2024) & (K Units)
Table 62. US & Canada Oncology Immuno Drug Sales by Country (2025-2030) & (K Units)
Table 63. Europe Oncology Immuno Drug Sales by Type (2019-2024) & (K Units)
Table 64. Europe Oncology Immuno Drug Sales by Type (2025-2030) & (K Units)
Table 65. Europe Oncology Immuno Drug Revenue by Type (2019-2024) & (US$ Million)
Table 66. Europe Oncology Immuno Drug Revenue by Type (2025-2030) & (US$ Million)
Table 67. Europe Oncology Immuno Drug Sales by Application (2019-2024) & (K Units)
Table 68. Europe Oncology Immuno Drug Sales by Application (2025-2030) & (K Units)
Table 69. Europe Oncology Immuno Drug Revenue by Application (2019-2024) & (US$ Million)
Table 70. Europe Oncology Immuno Drug Revenue by Application (2025-2030) & (US$ Million)
Table 71. Europe Oncology Immuno Drug Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 72. Europe Oncology Immuno Drug Revenue by Country (2019-2024) & (US$ Million)
Table 73. Europe Oncology Immuno Drug Revenue by Country (2025-2030) & (US$ Million)
Table 74. Europe Oncology Immuno Drug Sales by Country (2019-2024) & (K Units)
Table 75. Europe Oncology Immuno Drug Sales by Country (2025-2030) & (K Units)
Table 76. China Oncology Immuno Drug Sales by Type (2019-2024) & (K Units)
Table 77. China Oncology Immuno Drug Sales by Type (2025-2030) & (K Units)
Table 78. China Oncology Immuno Drug Revenue by Type (2019-2024) & (US$ Million)
Table 79. China Oncology Immuno Drug Revenue by Type (2025-2030) & (US$ Million)
Table 80. China Oncology Immuno Drug Sales by Application (2019-2024) & (K Units)
Table 81. China Oncology Immuno Drug Sales by Application (2025-2030) & (K Units)
Table 82. China Oncology Immuno Drug Revenue by Application (2019-2024) & (US$ Million)
Table 83. China Oncology Immuno Drug Revenue by Application (2025-2030) & (US$ Million)
Table 84. Asia Oncology Immuno Drug Sales by Type (2019-2024) & (K Units)
Table 85. Asia Oncology Immuno Drug Sales by Type (2025-2030) & (K Units)
Table 86. Asia Oncology Immuno Drug Revenue by Type (2019-2024) & (US$ Million)
Table 87. Asia Oncology Immuno Drug Revenue by Type (2025-2030) & (US$ Million)
Table 88. Asia Oncology Immuno Drug Sales by Application (2019-2024) & (K Units)
Table 89. Asia Oncology Immuno Drug Sales by Application (2025-2030) & (K Units)
Table 90. Asia Oncology Immuno Drug Revenue by Application (2019-2024) & (US$ Million)
Table 91. Asia Oncology Immuno Drug Revenue by Application (2025-2030) & (US$ Million)
Table 92. Asia Oncology Immuno Drug Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 93. Asia Oncology Immuno Drug Revenue by Region (2019-2024) & (US$ Million)
Table 94. Asia Oncology Immuno Drug Revenue by Region (2025-2030) & (US$ Million)
Table 95. Asia Oncology Immuno Drug Sales by Region (2019-2024) & (K Units)
Table 96. Asia Oncology Immuno Drug Sales by Region (2025-2030) & (K Units)
Table 97. Middle East, Africa and Latin America Oncology Immuno Drug Sales by Type (2019-2024) & (K Units)
Table 98. Middle East, Africa and Latin America Oncology Immuno Drug Sales by Type (2025-2030) & (K Units)
Table 99. Middle East, Africa and Latin America Oncology Immuno Drug Revenue by Type (2019-2024) & (US$ Million)
Table 100. Middle East, Africa and Latin America Oncology Immuno Drug Revenue by Type (2025-2030) & (US$ Million)
Table 101. Middle East, Africa and Latin America Oncology Immuno Drug Sales by Application (2019-2024) & (K Units)
Table 102. Middle East, Africa and Latin America Oncology Immuno Drug Sales by Application (2025-2030) & (K Units)
Table 103. Middle East, Africa and Latin America Oncology Immuno Drug Revenue by Application (2019-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Oncology Immuno Drug Revenue by Application (2025-2030) & (US$ Million)
Table 105. Middle East, Africa and Latin America Oncology Immuno Drug Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 106. Middle East, Africa and Latin America Oncology Immuno Drug Revenue by Country (2019-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America Oncology Immuno Drug Revenue by Country (2025-2030) & (US$ Million)
Table 108. Middle East, Africa and Latin America Oncology Immuno Drug Sales by Country (2019-2024) & (K Units)
Table 109. Middle East, Africa and Latin America Oncology Immuno Drug Sales by Country (2025-2030) & (K Units)
Table 110. Bristol-Myers Squibb Company Information
Table 111. Bristol-Myers Squibb Description and Major Businesses
Table 112. Bristol-Myers Squibb Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Bristol-Myers Squibb Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 114. Bristol-Myers Squibb Recent Developments
Table 115. Merck & Co Company Information
Table 116. Merck & Co Description and Major Businesses
Table 117. Merck & Co Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Merck & Co Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 119. Merck & Co Recent Developments
Table 120. Roche AG Company Information
Table 121. Roche AG Description and Major Businesses
Table 122. Roche AG Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 123. Roche AG Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 124. Roche AG Recent Developments
Table 125. AstraZeneca Company Information
Table 126. AstraZeneca Description and Major Businesses
Table 127. AstraZeneca Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 128. AstraZeneca Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 129. AstraZeneca Recent Developments
Table 130. Sanofi S.A. Company Information
Table 131. Sanofi S.A. Description and Major Businesses
Table 132. Sanofi S.A. Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 133. Sanofi S.A. Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 134. Sanofi S.A. Recent Developments
Table 135. Dendreon Pharmaceuticals Company Information
Table 136. Dendreon Pharmaceuticals Description and Major Businesses
Table 137. Dendreon Pharmaceuticals Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 138. Dendreon Pharmaceuticals Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 139. Dendreon Pharmaceuticals Recent Developments
Table 140. Novartis Company Information
Table 141. Novartis Description and Major Businesses
Table 142. Novartis Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 143. Novartis Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 144. Novartis Recent Developments
Table 145. Gilead Sciences Inc. Company Information
Table 146. Gilead Sciences Inc. Description and Major Businesses
Table 147. Gilead Sciences Inc. Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 148. Gilead Sciences Inc. Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 149. Gilead Sciences Inc. Recent Developments
Table 150. Merck KGaA Company Information
Table 151. Merck KGaA Description and Major Businesses
Table 152. Merck KGaA Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 153. Merck KGaA Oncology Immuno Drug Product Model Numbers, Pictures, Descriptions and Specifications
Table 154. Merck KGaA Recent Developments
Table 155. Key Raw Materials Lists
Table 156. Raw Materials Key Suppliers Lists
Table 157. Oncology Immuno Drug Distributors List
Table 158. Oncology Immuno Drug Customers List
Table 159. Oncology Immuno Drug Market Trends
Table 160. Oncology Immuno Drug Market Drivers
Table 161. Oncology Immuno Drug Market Challenges
Table 162. Oncology Immuno Drug Market Restraints
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources
List of Figures
Figure 1. Oncology Immuno Drug Product Picture
Figure 2. Global Oncology Immuno Drug Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Oncology Immuno Drug Market Share by Type in 2023 & 2030
Figure 4. Immune Checkpoint Inhibitors Product Picture
Figure 5. Cytokine-Based Immunotherapy Product Picture
Figure 6. Cancer Vaccines Product Picture
Figure 7. CAR-T Cell Therapy Product Picture
Figure 8. Other Product Picture
Figure 9. Global Oncology Immuno Drug Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
Figure 10. Global Oncology Immuno Drug Market Share by Application in 2023 & 2030
Figure 11. Hospitals
Figure 12. Drugstores
Figure 13. Others
Figure 14. Oncology Immuno Drug Report Years Considered
Figure 15. Global Oncology Immuno Drug Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 16. Global Oncology Immuno Drug Revenue 2019-2030 (US$ Million)
Figure 17. Global Oncology Immuno Drug Revenue Market Share by Region in Percentage: 2023 Versus 2030
Figure 18. Global Oncology Immuno Drug Revenue Market Share by Region (2019-2030)
Figure 19. Global Oncology Immuno Drug Sales 2019-2030 ((K Units)
Figure 20. Global Oncology Immuno Drug Sales Market Share by Region (2019-2030)
Figure 21. US & Canada Oncology Immuno Drug Sales YoY (2019-2030) & (K Units)
Figure 22. US & Canada Oncology Immuno Drug Revenue YoY (2019-2030) & (US$ Million)
Figure 23. Europe Oncology Immuno Drug Sales YoY (2019-2030) & (K Units)
Figure 24. Europe Oncology Immuno Drug Revenue YoY (2019-2030) & (US$ Million)
Figure 25. China Oncology Immuno Drug Sales YoY (2019-2030) & (K Units)
Figure 26. China Oncology Immuno Drug Revenue YoY (2019-2030) & (US$ Million)
Figure 27. Asia (excluding China) Oncology Immuno Drug Sales YoY (2019-2030) & (K Units)
Figure 28. Asia (excluding China) Oncology Immuno Drug Revenue YoY (2019-2030) & (US$ Million)
Figure 29. Middle East, Africa and Latin America Oncology Immuno Drug Sales YoY (2019-2030) & (K Units)
Figure 30. Middle East, Africa and Latin America Oncology Immuno Drug Revenue YoY (2019-2030) & (US$ Million)
Figure 31. The Oncology Immuno Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023
Figure 32. The Top 5 and 10 Largest Manufacturers of Oncology Immuno Drug in the World: Market Share by Oncology Immuno Drug Revenue in 2023
Figure 33. Global Oncology Immuno Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 34. Global Oncology Immuno Drug Sales Market Share by Type (2019-2030)
Figure 35. Global Oncology Immuno Drug Revenue Market Share by Type (2019-2030)
Figure 36. Global Oncology Immuno Drug Sales Market Share by Application (2019-2030)
Figure 37. Global Oncology Immuno Drug Revenue Market Share by Application (2019-2030)
Figure 38. US & Canada Oncology Immuno Drug Sales Market Share by Type (2019-2030)
Figure 39. US & Canada Oncology Immuno Drug Revenue Market Share by Type (2019-2030)
Figure 40. US & Canada Oncology Immuno Drug Sales Market Share by Application (2019-2030)
Figure 41. US & Canada Oncology Immuno Drug Revenue Market Share by Application (2019-2030)
Figure 42. US & Canada Oncology Immuno Drug Revenue Share by Country (2019-2030)
Figure 43. US & Canada Oncology Immuno Drug Sales Share by Country (2019-2030)
Figure 44. U.S. Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 45. Canada Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 46. Europe Oncology Immuno Drug Sales Market Share by Type (2019-2030)
Figure 47. Europe Oncology Immuno Drug Revenue Market Share by Type (2019-2030)
Figure 48. Europe Oncology Immuno Drug Sales Market Share by Application (2019-2030)
Figure 49. Europe Oncology Immuno Drug Revenue Market Share by Application (2019-2030)
Figure 50. Europe Oncology Immuno Drug Revenue Share by Country (2019-2030)
Figure 51. Europe Oncology Immuno Drug Sales Share by Country (2019-2030)
Figure 52. Germany Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 53. France Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 54. U.K. Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 55. Italy Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 56. Russia Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 57. China Oncology Immuno Drug Sales Market Share by Type (2019-2030)
Figure 58. China Oncology Immuno Drug Revenue Market Share by Type (2019-2030)
Figure 59. China Oncology Immuno Drug Sales Market Share by Application (2019-2030)
Figure 60. China Oncology Immuno Drug Revenue Market Share by Application (2019-2030)
Figure 61. Asia Oncology Immuno Drug Sales Market Share by Type (2019-2030)
Figure 62. Asia Oncology Immuno Drug Revenue Market Share by Type (2019-2030)
Figure 63. Asia Oncology Immuno Drug Sales Market Share by Application (2019-2030)
Figure 64. Asia Oncology Immuno Drug Revenue Market Share by Application (2019-2030)
Figure 65. Asia Oncology Immuno Drug Revenue Share by Region (2019-2030)
Figure 66. Asia Oncology Immuno Drug Sales Share by Region (2019-2030)
Figure 67. Japan Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 68. South Korea Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 69. China Taiwan Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 70. Southeast Asia Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 71. India Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 72. Middle East, Africa and Latin America Oncology Immuno Drug Sales Market Share by Type (2019-2030)
Figure 73. Middle East, Africa and Latin America Oncology Immuno Drug Revenue Market Share by Type (2019-2030)
Figure 74. Middle East, Africa and Latin America Oncology Immuno Drug Sales Market Share by Application (2019-2030)
Figure 75. Middle East, Africa and Latin America Oncology Immuno Drug Revenue Market Share by Application (2019-2030)
Figure 76. Middle East, Africa and Latin America Oncology Immuno Drug Revenue Share by Country (2019-2030)
Figure 77. Middle East, Africa and Latin America Oncology Immuno Drug Sales Share by Country (2019-2030)
Figure 78. Brazil Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 79. Mexico Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 80. Turkey Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 81. Israel Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 82. GCC Countries Oncology Immuno Drug Revenue (2019-2030) & (US$ Million)
Figure 83. Oncology Immuno Drug Value Chain
Figure 84. Oncology Immuno Drug Production Process
Figure 85. Channels of Distribution
Figure 86. Distributors Profiles
Figure 87. Bottom-up and Top-down Approaches for This Report
Figure 88. Data Triangulation
Figure 89. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Wireless Split Keyboard Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 18, 25
Global Ergonomic Adjustable Computer Chair Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 18, 25
Global Trackless Keyboard Tray Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 18, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232